Rekha Hemrajani
CIK: 0001771213
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 17, 2026MXCT
MAXCYTE, INC.
Award(A)Direct30.4K shares- - Jun 10, 2026BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
22K shares- - Jun 3, 2026LBRX
LB PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
10K shares- - Jan 20, 2026ALXO
ALX ONCOLOGY HOLDINGS INC
Award(A)DirectStock option (right to buy)
40.4K shares- - Sep 10, 2025LBRX
LB PHARMACEUTICALS INC
Award(A)DirectStock Option (Right to Buy)
22.4K shares- - Jun 25, 2025MXCT
MAXCYTE, INC.
Sale(S)Direct10.7K shares at avg. $2.09$22K - Jun 18, 2025MXCT
MAXCYTE, INC.
Award(A)Direct29.2K shares- - Jun 5, 2025BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
22K shares- - Jan 21, 2025ALXO
ALX ONCOLOGY HOLDINGS INC
Award(A)DirectStock Option (right to buy)
40.4K shares- - Dec 2, 2024ALXO
ALX ONCOLOGY HOLDINGS INC
Purchase(P)Direct30K shares at avg. $1.55$46K - Sep 27, 2024BIOA
BioAge Labs, Inc.
Purchase(P)Direct3K shares at avg. $18.00$54K - Sep 25, 2024BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
15K shares- - Apr 17, 2024BIOA
BioAge Labs, Inc.
Award(A)DirectStock Option (Right to Buy)
28.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 17, 2026 |  MXCT MAXCYTE, INC. | Award(A) | 30,421 | - | $0 | Direct |
| Jun 10, 2026 |  BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| Jun 3, 2026 |  LBRX LB PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Jan 20, 2026 |  ALXO ALX ONCOLOGY HOLDINGS INC | Award(A) Stock option (right to buy) | 40,400 | - | - | Direct |
| Sep 10, 2025 | LBRX LB PHARMACEUTICALS INC | Award(A) Stock Option (Right to Buy) | 22,449 | - | - | Direct |
| Jun 25, 2025 | MXCT MAXCYTE, INC. | Sale(S) | 10,684 | $2.09 | $22,378 | Direct |
| Jun 18, 2025 | MXCT MAXCYTE, INC. | Award(A) | 29,210 | - | - | Direct |
| Jun 5, 2025 | BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 22,000 | - | - | Direct |
| Jan 21, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | Award(A) Stock Option (right to buy) | 40,400 | - | - | Direct |
| Dec 2, 2024 | ALXO ALX ONCOLOGY HOLDINGS INC | Purchase(P) | 30,000 | $1.55 | $46,404 | Direct |
| Sep 27, 2024 | BIOA BioAge Labs, Inc. | Purchase(P) | 3,000 | $18.00 | $54,000 | Direct |
| Sep 25, 2024 | BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 15,000 | - | - | Direct |
| Apr 17, 2024 | BIOA BioAge Labs, Inc. | Award(A) Stock Option (Right to Buy) | 28,497 | - | - | Direct |
1-13 of 13 transactions
About Hemrajani Rekha
Hemrajani Rekha (SEC CIK 0001771213) files insider reports with the SEC as Director of MAXCYTE, INC. (MXCT), Director of BioAge Labs, Inc. (BIOA) and Director of LB PHARMACEUTICALS INC (LBRX). Signal8 also holds filings tied to 1 other company.
Signal8 holds 14 ownership filings by Hemrajani Rekha (2 Form 3, 12 Form 4), filed between Sep 25, 2024 and Jun 22, 2026. Those filings report 13 transactions, from Apr 17, 2024 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hemrajani Rekha's filings is in NEW YORK, NY.
Recent filings by Hemrajani Rekha
- Jun 17, 2026: Grant or award of MXCT shares (Form 4, code A).
- Jun 10, 2026: Grant or award of BIOA derivative securities (Form 4, code A).
- Jun 3, 2026: Grant or award of LBRX derivative securities (Form 4, code A).
- Jan 20, 2026: Grant or award of ALXO derivative securities (Form 4, code A).
- Sep 10, 2025: Grant or award of LBRX derivative securities (Form 4, code A).
Other insiders filing for MAXCYTE, INC. (MXCT)
- Johnston John Joseph, Director
- Erck Stanley C, Director
- DOUGLAS RICHARD, Director
- Collins Cynthia, Director
- Brooke William W, Director
- BALTHROP PATRICK J, Director